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Abstract
Studies on HIV-1 mucosal transmission to evaluate early events in pathogenesis and the development of effective preventive/prophylactic
methods have thus far been hampered by the lack of a suitable animal model susceptible to HIV-1 infection by either vaginal and/or rectal routes.
In this regard, while primate-SIV/SHIV and cat-FIV models provided useful surrogate platforms to derive comparative data, these viruses are
distinct and different from that of HIV-1. Therefore an optimal model that permits direct study of HIV-1 transmission via mucosal routes is highly
desirable. The new generation of humanized NOD/SCID BLT, NOD/SCIDγc−/−, and Rag2−/−γc−/− mouse models show great promise to achieve
this goal. Here, we show that humanized Rag2−/−γc−/− mice (RAG-hu) engrafted with CD34 hematopoietic progenitor cells harbor HIV-1-
susceptible human cells in the rectal and vaginal mucosa and are susceptible to HIV-1 infection when exposed to cell-free HIV-1 either via vagina
or rectum. Infection could be established without any prior hormonal conditioning or mucosal abrasion. Both R5 and X4 tropic viruses were
capable of mucosal infection resulting in viremia and associated helper T cell depletion. There was systemic spread of the virus with infected cells
detected in different organs including the intestinal mucosa. R5 virus was highly efficient in mucosal transmission by both routes whereas X4
virus was relatively less efficient in causing infection. HIV-1 infection of RAG-hu mice by vaginal and rectal routes as shown here represents the
first in vivo model of HIV-1 transmission across intact mucosal barriers and as such may prove very useful for studying early events in HIV-1
pathogenesis in vivo, as well as the testing of microbicides, anti-HIV vaccines/therapeutics, and other novel strategies to prevent HIV-1
transmission.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV/AIDS pathogenesis; HIV vaginal and rectal transmission; Microbicides; Humanized mice; HIV-1 mucosal transmission/infection; Animal disease
models; Hematopoietic stem cells; SCID-hu mice; Rag2−/−γc−/− mice; RAG-hu miceBackground
Infection via the mucosal surfaces constitutes the predomi-
nant natural mode of transmission of HIV/AIDS (Pope and
Haase, 2003). This most commonly involves transmission of
the virus by the heterosexual vaginal route or the rectal route
during homosexual contact. Detailed studies on the early
dynamic interactions between HIV-1 target cells, namely the
macrophages and dendritic cells during initial infection with the⁎ Corresponding author.
E-mail address: akkina@colostate.edu (R. Akkina).
1 The first two authors had equal commitment in this project.
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doi:10.1016/j.virol.2007.11.020commonly transmitted R5 tropic virus and its subsequent
dissemination in the body have so far been hampered by the
lack of a suitable animal model that permits HIV-1 infection via
mucosal routes (Hladik et al., 2007). In this regard, the rhesus
macaque model using SHIVand SIVor the cat model involving
FIV have been useful in deriving valuable comparative
pathogenesis data and in evaluation of a number of vaccine
candidates and microbicides (Burkhard and Dean, 2003; Miller
et al., 1989; Spira et al., 1996). However, SIV and FIV are
distinct viruses from that of HIV-1 and differ in terms of their
viral genetic make up and viral–host interactions. Thus, animal
model systems that employ HIV-1 itself to study pathogenesis
and treatment modalities are continuously being sought.
Table 1
Summary of human cell engraftment in mice used for R5 tropic HIV-1 mucosal
infection
Vaginal infection Rectal infection
Mouse Gender Peripheral
blood
engraftment
CD4:
CD8
Mouse Gender Peripheral
blood
engraftment
CD4:
CD8
213 F 74.4% 2.4:1 234 M 63.8% 3.3:1
217 F 54.2% 2.3:1 235 M 71.2% 6.1:1
238 F 77.6% 3.4:1 236 M 77.6% 2.3:1
258 F 69.4% 2.2:1 257 M 73.7% 1.2:1
259 F 58.6% 1.3:1 260 F 88.2% 1.7:1
264 F 77.4% 3.5:1 261 F 86.9% 2.0:1
265 F 89.0% 2.0:1 262 M 82.2% 1.8:1
266 F 80.7% 3.5:1 263 M 73.7% 2.4:1
200 F 8.2% 1.4:1 216 F 36.5% 1.0:1
Mean±
SD
65.5±
24.0%
72.6±
15.6%
Human cell engraftment levels, pre-infection CD4:CD8 T cell ratios, and gender
are provided along with the route of infection used for each mouse. F=female,
M=male.
Table 2
Summary of human cell engraftment in mice used for X4 tropic HIV-1 mucosal
infection
Vaginal infection Rectal infection
Mouse Gender Peripheral
blood
engraftment
CD4:
CD8
Mouse Gender Peripheral
blood
engraftment
CD4:
CD8
300 F 68.4% 1.6:1 296 M 18.3% 1.2:1
301 F 77.1% 1.3:1 297 M 41.6% 1.2:1
318 F 83.3% 1.1:1 310 F 81.6% 1.3:1
319 F 88.9% 1.5:1 313 F 31.0% 1.0:1
320 F 85.7% 3.9:1 315 F 7.4% 1.0:1
Mean±
SD
80.7±8.1% 36.0±
28.6%
Human cell engraftment levels, pre-infection CD4:CD8 Tcell ratios, and gender are
provided alongwith the route of infection used for eachmouse. F=female,M=male.
343B.K. Berges et al. / Virology 373 (2008) 342–351Humanized mice have filled this gap somewhat by providing a
platform in which human target cells are evaluated in terms of
viral susceptibility and associated helper Tcell loss. During nearly
the last two decades, two conventional human–mouse chimeric
models, namely the hu-PBL-SCIDmouse with transplanted adult
human PBLs, and the SCID-hu mouse model with transplanted
human thymus and liver tissues played a key role in pathogenesis
studies using a human hemato-lymphoid system (Jamieson et al.,
1996; Mosier, 1996; Shultz et al., 2007). However, infection of
these mice was achieved by injection into the peritoneal cavity or
into the thy/liv organ. Attempts to transmit the virus by mucosal
routes by either using cell-free virus or infected cells resulted in
inconsistent infection rates. However prior hormonal condition-
ing to diminish the mucosal thickness resulted in increased
infection rates (D'Cruz and Uckun, 2007; Khanna et al., 2002;
Olmsted et al., 2005). Furthermore, the nature and breadth of the
resident human cell types and their tissue distribution in the intact
host in these models was less than optimal due to the absence of
continual de novo hematopoiesis and skewed production of
certain cells such as primarily T cells as seen in the SCID-hu
mouse model. Although HIV-1 infection of the T cells and
monocytes/macrophages ensues, infection kinetics predomi-
nantly represent an acute mode with a consequent rapid helper
T cell loss. Thus the chronic nature and prolonged T cell loss as
seen in a natural human HIV-1 infection are not adequately
mimicked in these models in addition to lack of efficient mucosal
viral transmission.
Recent exciting advancements have resulted in the produc-
tion of improved humanized mice. Transplantation of human
hematopoietic stem cells (CD34+ cells) into novel immunodefi-
cient mice with additional mutations and much lower innate
immunity have permitted higher engraftment levels and sus-
tained multilineage human hematopoiesis. These new models
include the NOD/SCIDγc−/− and Rag2−/−γc−/− strains recon-
stituted with human CD34+ cells. Additionally, an innovative
improvement of the standard SCID-hu model involved trans-plantation of thymic and liver tissues under the kidney capsule of
NOD-SCID mice followed by reconstitution with autologous
human CD34+ cells (BLT mice). Multilineage hematopoiesis
with the generation of HIV-susceptible CD4+ T cells, macro-
phages, monocytes, and dendritic cells in addition to B cells with
a capacity for primary human immune responses distinguish
these newer humanized mouse models (Ito et al., 2002; Melkus
et al., 2006; Traggiai et al., 2004). A number of groups including
ours have demonstrated the utility of these humanized mice as
improved models for HIV-1 infection by showing chronic
viremia lasting several months by both R5 and X4 tropic viral
strains, virus replication in a variety of lymphoid and non-
lymphoid organs including thymus, lymph nodes, spleen, lung,
gut-associated lymphoid tissue, and male and female reproduc-
tive tracts. Viral infection leads to gradual CD4+ Tcell depletion.
Furthermore, humoral immune responses against HIV-1 could
also be seen to some extent (An et al., 2007; Baenziger et al.,
2006; Berges et al., 2006; Gorantla et al., 2006; Sun et al., 2007;
Watanabe et al., 2007; Zhang et al., 2006).
However, a major deviation in these ground-breaking studies
from that of natural infection was that the routes used for
infection, namely, the intraperitoneal injection or intravenous
injection, bypassed the mucosal barriers. While these studies
have conclusively demonstrated efficient infection by HIV-1,
the inoculation methods used are relatively rare routes of
exposure in humans. As pointed out above, the most common
route of HIV-1 infection is across the mucosa during vaginal or
rectal intercourse (Pope and Haase, 2003). In a recent attempt to
introduce HIV-1 by a natural route, studies of Sun et al. dem-
onstrated the presence of HIV-1 susceptible cells in the mucosa
of humanized BLT mice. They achieved successful HIV-1
infection via rectal exposure. Sustained viremia with associated
productive infection of lymphoid cells in different organs and a
consequent helper T cell loss was demonstrated. However, it
was necessary to cause intentional abrasion of the rectal epi-
thelium prior to viral exposure resulting in an artificial break of
mucosal barriers (Sun et al., 2007). To truly mimic the natural
and predominant mode of HIV-1 infection, one must demon-
strate a successful infection via vaginal or rectal routes without
overt epithelial abrasion. Thus far as pointed out above, this has
been achieved only with HIV-1-related viruses: SIV or SHIV
344 B.K. Berges et al. / Virology 373 (2008) 342–351infection of the rhesus macaque and FIV infection of the cat.
Although good substitutes, inherent limitations also exist with
the currently employed in vitro models of HIV-1 infection of
human vaginal tissue explants (Collins et al., 2000). The avail-
ability of a small animal model to directly study HIV-1 mucosal
transmission combined with human mucosal immunity would
greatly facilitate the understanding of the transmission mechan-
ism and could thereby lead to the development of novel
strategies to protect against mucosal infection.
With these criteria in mind, we evaluated RAG-hu mice for
their susceptibility to HIV-1 infection via the mucosal route.
Here, we show that these humanized mice harbor human Tcells,
macrophages and dendritic cells in the vaginal and rectal
mucosa. Further, they are readily infected by R5 tropic HIV-1
introduced into either the vaginal or rectal cavities, with viremia
detected within a week post-infection. Interestingly, we also
show that X4 tropic virus can cause successful infection through
the vaginal and rectal routes but not as efficiently as R5 tropicFig. 1. RAG-hu mouse mucosal tissues are populated by HIV-1-susceptible human ce
intestines were dissected and frozen. Tissue sections from engrafted mice were immu
markers CD45 (A–C), CD3 (D–F), CD68 (G–I), and CD4 (J–L). Unengrafted tissue
and CD68 (data not shown).virus. This system can be potentially very valuable for
pathogenesis as well as prevention studies involving micro-
bicides and therapeutic vaccines.
Results
R5 tropic HIV-1 exposure of RAG-hu mice by vaginal and
rectal mucosal routes leads to productive infection and
sustained viremia
Humanized mice were prepared as described previously by
injecting CD34+ cells into conditioned neonatal Rag2−/−γc−/−
mice (Berges et al., 2006; Traggiai et al., 2004). The mean
human cell engraftment level in peripheral blood for mice used
in these experiments was 65% as assessed by FACS for the
CD45 marker (summarized in Tables 1 and 2). Humanized mice
with both high and low engraftment levels were utilized to
determine their susceptibility to infection via mucosal routes.lls. Engrafted and unengrafted mice were sacrificed and vagina, rectum, and large
nostained with fluorescent-labeled antibodies for the presence of the human cell
s were negative for the human cell markers CD45 (M–O), as well as CD3, CD4,
Fig. 2. HIV-1 viral load in peripheral blood followingmucosal infection. Infected
mouse plasma was collected weekly and RNAwas extracted. Viral load (in RNA
copies/ml plasma) was determined by Q-RT-PCR as described in Methods.
(A) R5 virus infection. (B) X4 virus infection.Mice that failed to become viremic
are not included.
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present in the RAG-hu mouse mucosal tissues. Specifically,
vaginal, rectal, and gut tissues were stained for the presence
of human leukocytes (CD45), T cells (CD3), macrophages/
dendritic cells (CD68), and for cells bearing the primary HIV-1
receptor CD4 (Fig. 1). All of the above tissues were positive for
cells staining for the pan-leukocyte marker CD45, thus
indicating the presence of human leukocytes (Figs. 1A–C).
The presence of human T cells was revealed by positive staining
for CD3 (Figs. 1D–F) and CD68+ macrophages and/or dendritic
cells were also detected (Figs. 1G–I). Finally, CD4+ cells were
also detected in each tissue (Figs. 1J–L). Unengrafted tissues
were negative for human CD45 or any other human stains
(Figs. 1M–O and data not shown). In addition, no staining was
evident when primary antibodies were omitted.
In the first series of experimental infections, we began with
R5 tropic HIV-1 infection of these mice by both vaginal and
rectal routes (n=9 each) as described in Methods. We initially
used the R5 tropic HIV-1 strain BaL-1 as it represents the class
of HIV-1 which is most readily transmitted and most commonly
detected following initial infection in humans (Berger et al.,
1999). The human cell engraftment levels of the mice chosen
for R5 viral infection averaged 65.5±24.0% for the vaginal
route and 72.6±15.6% for the rectal route (summarized in
Table 1). Mice were bled at weekly intervals and plasma viremia
was measured by Q-RT-PCR. All the mice infected by either
route (including female mice infected via the rectal route)
with R5 tropic HIV-1 became viremic by the first week post-
infection and this persisted throughout the 10-week observation
period (Fig. 2A), thus indicating successful infection and viral
maintenance in vivo. Two control, uninfected mice exhibited
undetectable viral load. As can be seen, viral load peaked during
7–8 weeks in vaginally infected mice whereas the peak viral
load was observed at an earlier stage between 5 and 7 weeks in
the rectally infected mice. At later time points, viral loads fell to
the levels seen during early weeks post-infection. The highest
viral titers reached were 6×107 RNA copies/ml at 7 weeks for a
vaginally infected mouse and 2×107 at 7 weeks for a rectally
infected mouse. In addition, virus was successfully re-isolated
from 6 out of 6 vaginally infected mice (4 weeks post-infection)
by co-culture, further establishing that the circulating virus
detected by Q-RT-PCR was indeed a viable, infectious virus
(data not shown).
Mucosal infection of RAG-hu mice with HIV-1 leads to
systemic viral dissemination and replication
Initial infection with HIV-1 at the portal of entry is believed
to be amplified locally and carried to local lymph nodes
followed by systemic dissemination to target cells in various
organ systems. Therefore, to provide additional evidence of
widespread infection following mucosal transmission of HIV-1,
a viremic mouse was sacrificed at 4 weeks post-infection.
Mesenteric lymph node, spleen, and intestinal tissue sections
were subjected to RNA in situ hybridization to detect HIV-1
sequences in infected cells (Fig. 3). Numerous HIV+ cells
were apparent in the lymph nodes (Fig. 3B), small intestines(Fig. 3D), and spleen (Fig. 3F), indicating viral spread and
productive infection of distant target cells. On the contrary, no
positive hybridization signal was detectable in uninfected
tissues (Figs. 3A, C, E) or on any tissues hybridized with a
sense probe (data not shown).
X4 tropic HIV-1 can also cause productive infection of RAG-hu
mice by vaginal and rectal routes
R5 tropic viruses are believed to have the greatest capacity
for infection via mucosal routes as these are the strains that are
generally isolated during the primary infection stage (Berger
et al., 1999). On the contrary, it is not clear if X4 tropic viruses
can efficiently spread via the mucosal route. Therefore, we
evaluated if X4 viruses can cause productive infection of RAG-
hu mice by either vaginal or rectal exposure. Similar protocols
as above were used for infection of humanized mice with the
X4 tropic HIV-1 strain NL4-3. We found that 4 out of 5 mice
infected by the vaginal route were positive for viremia during
the first week post-infection, with the highest viral load (9×105)
appearing at 5 weeks post-infection (Fig. 2B). In mice receiving
rectal infection with X4 virus, 2 out of 5 mice became viremic
during the first week, with the highest viral load (9×104)
appearing at 5 weeks (Fig. 2B). In all of the above X4 viral
infections, mice were either consistently positive for viremia or
never positive for viremia throughout the time course. To verify
Fig. 3. HIV-1 replication in proximal and distal organs following mucosal infection. Mucosally-infected mice were sacrificed and organs were collected and probed for
HIV-1 RNA using an env riboprobe by in situ hybridization. Mouse 262 was sacrificed at 4 weeks following rectal infection with HIV-1 BaL-1, and mouse 320 was
sacrificed at 8 weeks following rectal infection with HIV-1 NL4-3. (A, C, E) Uninfected tissue sections from mesenteric lymph node, small intestines, and spleen,
respectively. (B, D, F) R5 virus-infected tissue sections from mesenteric lymph node, small intestines, and spleen, respectively. (G, I) Uninfected tissue sections from
thymus and lymph node, respectively. (H, J) X4 virus-infected tissue sections from thymus and lymph node, respectively. Panels A, B, E, F: original magnification
600×. Panels C, D, G, H, I, J: original magnification 200×.
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lymph node tissue sections obtained from a viremic mouse at
8 weeks post-infection were subjected to RNA in situ
hybridization to detect HIV-1 sequences (Fig. 3). HIV-1+ cells
were detected in both thymus and lymph nodes (Figs. 3H, J)
while the uninfected sections were negative (Figs. 3G, I). Thus,
X4 tropic virus can also infect across both vaginal and rectal
routes and produce a disseminated infection.Both R5 and X4 HIV-1 strains can cause CD4+ T cell depletion
following infection via mucosal routes
CD4+ T cell loss is a hallmark of HIV-1 infection in the
human. In a typical case, helper T cell levels fall transiently
during the acute stage of infection followed by a rebound to a set
point for several months to years with an eventual depletion
leading to AIDS. To assess depletion of CD4+ Tcells, peripheral
Fig. 4. CD4+ T cell depletion following mucosal infection with HIV-1. Mice mucosally infected with HIV-1 were screened for CD4+ T cell depletion by FACS analysis
of peripheral blood cells stained with CD3 and CD4. The CD4:CD3 ratio reflects the percentage of CD3+ cells that were also CD4+ relative to total CD3+ cells. Since
individual mice have varying CD4:CD3 ratios, all data shown are standardized to the baseline values obtained prior to infection. (A) Mucosal infection with R5 tropic
virus. Vaginal infection, n=7. Rectal infection, n=9. Uninfected mice, n=2. (B) FACS dot plots from representative R5 virus-infected mice exposed either vaginally
or rectally. (C) Mucosal infection with X4 tropic virus. Vaginal infection, n=4. Rectal infection, n=2.
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virus and stained with CD3 and CD4 antibodies and assayed by
FACS as a ratio of CD4+CD3+ cells to CD4−CD3+ cells (Fig. 4).
CD4+ T cell levels in mice infected with R5 virus first began to
drop at 7 weeks post-infection and the greatest depletion was at
9 weeks, followed by a rebound to normal levels by week 11
(Fig. 4A). Representative FACS plots are shown in Fig. 4B.
CD4+ T cell depletion was more pronounced following vaginal
infection (~25% decrease) than for rectal infection (~10%decrease). Significant CD4+ Tcell loss approaching up to a 75%
decrease was also seen following X4 viral infection in a
vaginally-infected individual mouse (Fig. 4C).
Discussion
Improved humanized mouse models with a capacity for
sustained multilineage hematopoiesis have opened upmany new
exciting avenues of HIV-1 researchwhich until recently were not
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tuted with human CD34+ cells (RAG-hu mice) can be efficiently
infected with R5 tropic HIV-1, and remarkably also with X4
tropic HIV-1 across both the intact vaginal and rectal mucosa,
thus representing the first efficient in vivo model of HIV-1
mucosal transmission to human cells.
In previous efforts with a small animal model, studies on
mucosal transmission in conventional hu-PBL-SCID mice
showed inefficient viral transmission (D'Cruz and Uckun,
2007). In a recent report, studies of Sun et al. using an improved
humanized mouse model, namely the BLT mouse, demon-
strated successful intra-rectal transmission of HIV-1. Although
this represents a significant advancement over the previous
models, the rectum had to be manipulated to create abrasions
before exposure to HIV-1 for successful viral transmission.
Furthermore, vaginal transmission was not attempted, and these
studies were confined to transmission with an X4 tropic virus
not known to be the major transmitted virus by the mucosal
route (Sun et al., 2007). In contrast, in our present studies
successful HIV-1 transmission was obtained via both vaginal
and rectal routes without causing any artificial abrasions.
Infection with R5 tropic virus was highly efficient with all the
HIV-1 exposed mice becoming viremic within the first week.
This substantiates the previous notion that R5 tropic viruses are
the major strains transmitted by the natural mucosal route.
Surprisingly, we also found that even X4 tropic viruses can be
transmitted by natural routes. However, not all mice exposed to
the X4 tropic virus were successfully infected, indicating that
transmission is not as efficient as that achieved by R5 tropic
virus. Further, infection across the rectal mucosa with X4 tropic
virus was less efficient (40%, n=5) than across the vaginal
mucosa (80%, n=5), indicating that an intact rectal mucosa is
not as efficiently traversed by the X4 virus. A possible reason
may be that target T cells are not as abundant in the rectal
mucosa; this will require further investigation.
We also have shown that mucosally transmitted virus is spread
systemically to organs such as thymus, spleen and lymph nodes in
addition to the small intestines. Numerous infected cells were seen
similar to that in human infections. Characteristic CD4+ T cell
depletion is also evident in these mucosally infected mice. A
comparison of previous data on mice infected via the intraper-
itoneal route with the present vaginal/rectal infections revealed
similarities as well as minor differences: viral loads were fairly
similar, while CD4+ T cell depletion in peripheral blood varied
both in terms of the kinetics and the severity of depletion fol-
lowing R5 virus infection (less severe following mucosal infec-
tion). The more rapid and severe CD4+ T cell depletion following
intraperitoneal infection might be due to more immediate viral
access to large numbers of susceptible target cells compared to
mucosal infection, wherein the virus gains access to systemic
spread in a more gradual way. However, larger numbers of mice
need to be studied before further conclusions can be drawn. For
mucosal infection, CD4+ Tcell depletionwasmore pronounced in
mice infected with X4 tropic virus, even though viral loads were
comparable. This is consistent with previous studies in RAG-hu
micewhich showed that CD4+ Tcell depletion following infection
with R5 strains is less robust compared to that observed with X4viral infection, even though viral loads are similar (Baenziger
et al., 2006; Zhang et al., 2006).
To date, the best surrogate model for HIV-1 mucosal trans-
mission involved vaginal SIV and SHIV infections in non-
human primates (Miller et al., 1989; Spira et al., 1996), although
FIV infection of the cat (Burkhard and Dean, 2003) and in
vitro models of HIV-1 transmission across the human mucosal
tissue explants have also been valuable (Collins et al., 2000).
However, there are important differences and limitations be-
tween HIV-1 transmission to humanized mice and SIV trans-
mission models in macaques. In addition to SIV, SHIVand HIV-
1 being different viruses, the vaginal transmission model of SIV
in macaques is expensive and the use of large numbers of
animals is prohibitive. In contrast, large numbers of RAG-hu
mice can be generated at a fraction of the cost of similar
numbers of monkeys. Furthermore, RAG-hu mice are also
permissive to X4 tropic viral infection via the mucosal route
thereby broadening the scope of future intervention studies.
Thus, the present RAG-hu mouse model of mucosal HIV-1
transmission shows exquisite sensitivity to infection.
Many novel studies on HIV-1 pathogenesis using human
cells can now ensue with the advent of this new RAG-hu mouse
model of mucosal infection. For example, recent elegant in vitro
work using explant cultures of vaginal mucosa showed that the
initial R5 viral infection targeted cells such as Langerhans cells
before further viral spread (Hladik et al., 2007). The current
model will permit a more dynamic physiologic study of these
initial viral-cell interactions at the site of viral entry as well as
later spread to the draining lymph node in an intact animal.
Prophylactic measures involving anti-HIV-1 drugs can now be
tested using this model to evaluate protection from mucosal
transmission.
Vaginal and rectal microbicides can now be easily evaluated
in vivo on HIV-1 (McGowan, 2006; Veazey et al., 2005) itself in
a cost-efficient manner using large number of animals before
proceeding with further testing in more expensive monkey
models. In addition to conventional microbicides approaches,
novel molecules such as siRNAs are also currently being
investigated. In one recent study, the efficacy of an siRNA-based
microbicide was demonstrated against lethal vaginal challenge
of mice with herpes simplex virus (Palliser et al., 2006). With
regard to HIV-1, our laboratory has characterized several
effective siRNAs targeted to the HIV-1 co-receptors CXCR4
and CCR5 (Anderson and Akkina, 2005; Anderson and Akkina,
2007). These await testing against mucosal HIV-1 transmission.
Although the RAG-hu mouse model has not yet proved to be
ideal to demonstrate anti-HIV-1 humoral and cellular immune
responses, a recent report from our laboratory described the
production of neutralizing antibodies following challenge of
RAG-hu mice with Dengue virus (Kuruvilla et al., 2007),
indicating that specific immune responses can be generated to
other viruses. In the case of HIV-1, at the least, passive antibody
mediated protection against mucosal infection can now be exam-
ined using a natural route of challenge, thus permitting testing of
broadly neutralizing antibodies for their protective effects.
Although each novel humanized mouse model is unique, the
RAG-hu model of HIV-1 mucosal transmission offers many
349B.K. Berges et al. / Virology 373 (2008) 342–351technical and practical advantages over the recently described
BLT mouse model of rectal HIV-1 transmission (Sun et al.,
2007). First, it permits both vaginal and rectal mucosal trans-
mission across an intact mucosal barrier with a much lower input
virus. Second, preparation of RAG-hu mice is not as technically
intensive since no surgical procedure is required as is necessary
to generate BLT mice. Third, RAG-hu mice have a longer life
span compared to BLT mice (NOD mice experience a high
incidence of lymphomas), thus permitting long-term studies. For
example, the effect of microbicides on the mucosal epithelia
during long-term application can now be evaluated and whether
or not a microbicide which showed short-term protection can be
used long-term safely. Furthermore, for any large scale testing, a
sufficient cohort number of humanized mice are needed. In this
regard, greater numbers of RAG-hu mice can be generated per
human tissue donor versus BLT mice. Although these proof-of-
concept studies have established that efficient mucosal infection
is feasible in the humanized RAG-hu mice, many questions
remain and need to be further evaluated. Among these: What
is the minimal dose required to achieve consistent HIV-1 infec-
tion? Which cell type(s) are first infected in the mucosa and how
does the virus reach the regional lymph nodes for subsequent
systemic dissemination?
In summary, RAG-hu mice capable of multilineage human
hematopoiesis are exquisitely susceptible to mucosal transmis-
sion of HIV-1. Both R5 and X4 viruses can initiate mucosal
infection followed by viremia and associated T cell depletion.
Thus, this model will permit many new pathogenesis, pro-
phylactic and therapeutic studies on HIV-1.
Methods
Generation of humanized Rag2−/−γc−/− mice (RAG-hu mice)
Humanized BALB/c-Rag2−/−γc−/− mice were prepared as
described (Berges et al., 2006; Traggiai et al., 2004) with the
minor modification of using human fetal liver-derived CD34+
cells. Briefly, neonatal mice were conditioned by irradiating at
350 rads and then injected intrahepatically with 0.5–1×106
human CD34+ cells. Approximately 12 weeks post-reconstitu-
tion, mice were screened for human cell engraftment. Blood was
collected by tail bleed, and red blood cells were lysed using the
Whole Blood Erythrocyte Lysing Kit (R&D Systems, Minnea-
polis, MN). The white blood cell fraction was stained with
antibodies against the human pan-leukocyte marker CD45
(Caltag) and FACS analyzed as described (Berges et al., 2006).
Mice with varying human cell reconstitution levels were used to
determine mucosal HIV-1 infection susceptibility.
HIV-1 infection of RAG-hu mice
Humanized mice were infected with either cell-free HIV-1
strain BaL-1 (R5 tropic) or NL4-3 (X4 tropic) contained in the
original media used to produce the virus (RPMI 1640 medium
supplemented with 10% fetal bovine serum). Mice were allowed
to defecate prior to rectal inoculation so as to prevent immediate
expulsion of virus. Vaginal infections were performed in avolume of 50 μl (156 TCID50 of BaL-1 virus or 203 TCID50 of
NL4-3) and rectal infections were performed in a volume of
20 μl (BaL-1 virus at 62 TCID50; NL4-3 virus at 81 TCID50).
Sterile P200 tips that had been previously heated over a flame to
smooth any abrasive surfaces were used to deliver the virus.
Mice were held in an inverted position for 4min post-inoculation
to allow virus to adsorb and to prevent immediate discharge of
virus. Mice were monitored daily.
Cell culture and virus re-isolation
To re-isolate the circulating virus from infected mice by co-
culture, 150 μl of heparinized blood was collected by tail-bleed
and red blood cells were lysed.White blood cells were cultured in
Iscove's modified Dulbecco's medium (Invitrogen, Grand Island,
NY) supplemented with 10% FBS, PHA (1 μg/ml) and IL-2
(1 μg/ml) for 48 h, then co-cultured with 1×106 freshly isolated
and stimulated human PBMCs. Co-cultures were maintained in
IMDMwith 10% FBS, PHA (1 μg/ml) and IL-2 (1 μg/ml). After
1 week of co-culture, supernatants were assayed for the presence
of p24 by ELISA (Beckman Coulter, Fullerton, CA).
Measurement of viral load in plasma
To quantify cell-free HIV-1 by Q-RT-PCR, RNA was
extracted from 25 to 50 μl of EDTA-treated plasma using the
QIAamp Viral RNA kit (Qiagen, Valencia, CA). cDNAs were
produced with Superscript III reverse transcriptase (Invitrogen,
Carlsbad, CA) using a primer set specific for the HIV-1 LTR
sequence, and Q-PCR was performed with the same primer set
and a LTR-specific probe (Rouet et al., 2005) using Supermix
UDG (Invitrogen, Carlsbad, CA).
Flow cytometry
Whole blood was collected and red blood cells lysed as
reported previously (Berges et al., 2006). Peripheral blood cells
were stained for hCD3-PE and hCD4-PECy5 (Caltag) markers
and analyzed using a Coulter EPICS XL-MCL FACS analyzer
(Beckman Coulter, Fullerton, CA). CD4+ T cell levels were
calculated as a ratio of the entire CD3 population (CD4+CD3+:
CD4−CD3+). To establish baseline CD4+ T cell ratios, all mice
were analyzed prior to infection.
In situ hybridization for HIV-1 RNA
In situ hybridization was performed on 4-μm formalin-
fixed, paraffin-embedded tissue sections from thymus, mesen-
teric lymph nodes, spleen, and gut tissue from HIV-1 infected
and uninfected RAG-hu mice. At least three sections were
evaluated from each tissue. Hybridization was performed using
digoxigenin-labeled antisense and sense riboprobes specific for
HIV-1 env (nt 6411–6752) and detected using nitro blue
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate (NBT/
BCIP) as reported previously (Berges et al., 2005). Sections
were lightly counterstained with hematoxylin to enable visual-
ization of nuclei.
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Four micron frozen sections were fixed in 1% paraformal-
dehyde in Phosphate Buffered Saline for 20 min, washed in Tris
Buffered Saline (TBS), pH 7.6 (50 mM TRIS Hydrochloride,
150 mM Sodium Chloride) and blocked for 1 h with Vector
Mouse Ig Blocking Reagent (Vector Laboratories, Burlingame,
CA). After washing in TBS, slides were incubated 30 min with
primary antibodies diluted in TBS with 1% Bovine Serum
Albumin and 0.1% Sodium Azide (antibody diluent), followed
by three 10-min washes in TBS and a 15-min incubation with
Alexa Fluor® 488 Goat anti-Mouse IgG (Molecular Probes,
Eugene, OR) diluted in antibody diluent. After three washes in
TBS, sections were coverslipped using SlowFade® Gold
antifade reagent with DAPI (Molecular Probes). Slides were
viewed and imaged on a Leica DM5000B microscope (Leica,
Cambridge, England) equipped with epifluorescence and digital
monochrome camera (Leica DFC350FX) using Leica FW4000
software. Primary antibodies that were determined to not cross-
react with mouse antigens and used for staining were: CD3
clone UCHT1 (BD Biosciences Pharmingen, San Jose, CA),
CD4 clone RPA-T4 (BD Biosciences Pharmingen), CD45 LCA,
clone 2B11 + PD7/26 (DakoCytomation, Denmark) and CD68
clone EBM11 (DakoCytomation).
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